Trending...
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
- Permian Museum announces the addition of an Ancient Alien Artifacts photo gallery
WATERTOWN, Mass., June 18, 2024 ~ Remix Therapeutics, a clinical-stage biotechnology company, has recently announced the appointment of Dr. Maria Koehler as an independent director to their Board of Directors. This move comes as Remix continues to develop small molecule therapies that target RNA processing and address the underlying causes of various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
According to Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, Dr. Koehler's extensive industry knowledge and experience will be invaluable as the company advances its pipeline of RNA processing modulators. This includes their lead program REM-422, which is a first-in-class therapy.
Dr. Koehler brings over 20 years of experience in leading clinical and regulatory strategy operations for biotech and pharmaceutical companies focused on oncology research and development. She currently serves as the Chief Medical Officer at Repare Therapeutics, a clinical-stage precision oncology company. In addition, she has held executive and medical leadership roles at Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline.
More on The PennZone
- LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
- Kellyn Endorses National Push to Expand Food is Medicine
- LATO AI Automates Customer Communication to Help CSide Sports Academy and BAT 24 Nation Grow
- Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
- 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
Dr. Koehler's expertise also extends to academia, where she has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and as the director of the Bone Marrow Transplant Program at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician with an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Currently serving as an independent director on the boards of Ikena Oncology and Abdera Therapeutics, Dr. Koehler expressed her excitement about joining Remix during this pivotal time for the company. She believes that their innovative approach to reprogramming RNA processing holds great therapeutic potential and looks forward to working with Remix leadership and fellow board members to drive this science forward.
With Dr. Koehler's appointment, Remix is poised for success as they continue to make strides in developing groundbreaking therapies that target RNA processing. The company is confident that her expertise and guidance will be instrumental in their journey towards improving the lives of patients with various diseases.
0 Comments
Latest on The PennZone
- Slotozilla Reports Strong Growth in Q2 2026
- Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
- Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
- Flexible Plan Investments Names Carl Resnick President
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
- Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
- No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
- The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
- Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
- Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
- FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
- San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
- Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
- GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
- Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
- Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
- Colonial Nissan Earns Capital One Top Performing Dealership Award
- BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot